Naveed Aslam: Final Debarment Order
Naveed Aslam: Final Debarment Order — FDA update affecting Cosmetics & Personal-Care (MoCRA).
Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on September 25, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Cosmetics & Personal-Care (MoCRA) (indie beauty brands, contract manufacturers, private-label makers, importers/distributors) should confirm how it applies to their specific situation before acting. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed. Regulated niches like Cosmetics & Personal-Care (MoCRA) move faster than most operators can track by hand, which is why Aforeworn watches the official sources for you and flags every material change the moment it appears. Bookmark this briefing, share it with anyone on your team responsible for compliance, and check the source link above for the full official text before you make any decisions.
What changed
Naveed Aslam: Final Debarment Order
Who it affects
Cosmetics & Personal-Care (MoCRA) (indie beauty brands, contract manufacturers, private-label makers, importers/distributors)
What you must do
Read the update and assess whether your current setup needs to change.
Deadline
No fixed deadline was published, but changes like this are often enforced quickly — act promptly.
Source: https://www.federalregister.gov/documents/2026/09/25/2026-19654/naveed-aslam-final-debarment-order
Never miss a change like this again
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cosmetics & Personal-Care (MoCRA)
- Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application (NDA) 219694 for Atropine Sulfate Ophthalmic Solution, 0.01%
- Robotically-Assisted Surgical Devices-Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability
- Jeffrey Thies: Final Debarment Order
- Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Comments
- Connecticut Publishes Additional Information Regarding PFAS in Consumer Products Law - The National Law Review